CV NEWS FEED // The National Association of Pro-life Nurses President Dorothy Kane discussed nurses’ first-hand witness of the “devastating impact of chemical abortion drugs” in an exclusive interview with CatholicVote.
The National Association of Pro-life Nurses recently joined the plaintiffs in the critical Supreme Court case challenging the Food and Drug Administration’s removal of safeguards for the chemical abortion pill mifepristone. The Supreme Court heard oral arguments for the case, U.S. Food and Drug Administration v. Alliance for Hippocratic Medicine, on March 26.
“Nurses are front-line witnesses to the devastating impact of chemical abortion drugs,” Kane told CatholicVote in an email interview. “We see the women arriving in emergency rooms, hemorrhaging and suffering from life-threatening infections.”
Kane said she and the association hope the Supreme Court will hold the FDA accountable by restoring the safeguards for the drug.
She noted the immediate risks posed by mifepristone and that the drug has “documented risks of complications.”
“Women who consume chemical abortion drugs experience physical, emotional, and psychological side effects,” she said.
The FDA’s own warning label for the drug, she explained, states that almost 1 in 25 women who take mifepristone will suffer emergency medical complications.
“The elimination of in-person doctor visits endangers women, particularly those at risk for ectopic pregnancies,” Kane added.
>> Clinical Pharmacist Condemns Chemical Abortion Pill: ‘Isn’t a Medication at All’ <<
Kane said that human traffickers also benefit from easy-access chemical abortion pills.
“The FDA has empowered human traffickers and abusers to exploit victims through unfettered access to these high-risk drugs,” she stated.
Kane also responded to the claim that mifepristone is a necessary medication for some non-abortion-related treatments and that the Supreme Court’s decision on the case could affect access to those treatments.
“This landmark case is not about eliminating access to mifepristone, but rather restoring common-sense safeguards for women who consume these high-risk drugs,” she said. “While some highlight potential uses of mifepristone, safer and equally effective alternatives exist for conditions like miscarriage management or Cushing’s Syndrome.”
She added that patients’ health and safety should be healthcare providers’ top concerns.
“Frontline healthcare providers should be advocates for their patients, not profit-driven pharmaceutical companies,” Kane stated.
